Aptose Biosciences completes C$8 million share offering
December 10, 2013
8.00 Million CAD
On December 10, 2013, Aptose Biosciences completed its bought deal public offering of common shares.
The Company issued a total of 12,730,000 Offered Shares at C$0.55 per Offered Share, for aggregate gross proceeds of C$7 million. The Offering was sold to a syndicate of underwriters co-led by Clarus Securities Inc. and Canaccord Genuity Corp., and including Jennings Capital Inc. and D&D Securities Inc. and PowerOne Capital Markets Limited as a member of the selling group, upon the terms of an underwriting agreement entered into among the Company and the Underwriters. In addition, the Company granted the Underwriters an over-allotment option to purchase that number of additional common shares equal to 15% of the Offered Shares sold pursuant to the Offering at the Offering Price for a period ending 30 days following the closing of the Offering (the Over-Allotment Option).
On January 8, 2014, Aptose Biosciences announced that the underwriters exercised in full their over-allotment option to purchase an additional 1,909,500 common shares of the Company at C$0.55 per common share. As a result of the exercise of this over-allotment option, Aptose received additional gross proceeds of C$1 million and will have raised total gross proceeds of C$8 million from its public offering.
Aptose Biosciences, headquartered in Toronto, is a biopharmaceutical company focused on the discovery, research and development of anti-cancer therapies.
McCarthy Tétrault LLP represented Lorus Therapeutics, the issuer, with a team led by Charles-Antoine Soulière and including Myreille Gilbert, Annie Mailhot-Gamelin, Ian Michael and Jacob Stone.